Mutual Makes Last Plea To High Court For Post-Mensing Case

Law360, New York (November 15, 2012, 6:54 PM EST) -- Mutual Pharmaceutical Co. Inc. stressed Tuesday that if the U.S. Supreme Court did not review a First Circuit ruling over whether generic-drug companies can be targeted for design defect claims, it would allow a decision in direct conflict with its landmark Mensing ruling to stand.

The generics maker is petitioning the high court to take up and reverse the First Circuit's decision to uphold a $23 million award to a woman, Karen Bartlett, who suffered a near-fatal reaction after taking Mutual's drug Sulindac for pain in...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.